Research ArticleArticle
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist
Mark C. Genovese, Désirée M. van der Heijde, Edward Keystone, Alberto J. Spindler, Claude Benhamou, Arthur Kavanaugh, Edward Fudman, Kathy Lampl, Chris O’Brien, Emma L. Duffield, Jeffrey Poiley and Michael E. Weinblatt
The Journal of Rheumatology September 2014, jrheum.140238; DOI: https://doi.org/10.3899/jrheum.140238
Mark C. Genovese
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Désirée M. van der Heijde
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Edward Keystone
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Alberto J. Spindler
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Claude Benhamou
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Arthur Kavanaugh
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Edward Fudman
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Kathy Lampl
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Chris O’Brien
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Emma L. Duffield
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Jeffrey Poiley
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Michael E. Weinblatt
From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA. Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche. A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca. J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera. M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital. Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication July 24, 2014.
Article Information
jrheum.140238
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online September 15, 2014.
Article Versions
- You are currently viewing a Latest version of this article (September 15, 2014 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2014 The Journal of Rheumatology
Author Information
- Mark C. Genovese,
- Désirée M. van der Heijde,
- Edward Keystone,
- Alberto J. Spindler,
- Claude Benhamou,
- Arthur Kavanaugh,
- Edward Fudman,
- Kathy Lampl,
- Chris O’Brien,
- Emma L. Duffield,
- Jeffrey Poiley and
- Michael E. Weinblatt
- From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women’s Hospital, Boston, Massachusetts, USA.
Clinical study sponsored by AstraZeneca. M. Genovese has received research grants and consulting fees from AstraZeneca and Rigel. D. van der Heijde has received consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly and Co., GSK, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex, and serves as director at Imaging Rheumatology BV. E. Keystone has obtained research grants from Abbott, Amgen, AstraZeneca, Baylis Medical, Bristol-Myers Squibb, Roche, Janssen, Eli Lilly and Co., Novartis, Pfizer, Sanofi-Aventis, and UCB. He also has consulting agreements and/or advisory board membership with Abbott, AstraZeneca, Biotest, Bristol-Myers Squibb, Roche, Genentech Inc., Janssen Inc., Eli Lilly and Co., Merck, Nycomed, Pfizer, and UCB, and speaker honoraria agreements with Abbott, AstraZeneca, Bristol-Myers Squibb, Roche Inc., Janssen Inc., Pfizer, UCB, and Amgen. A. Spindler is a clinical study investigator for AstraZeneca. C. Benhamou has received research grants from Servier and Amgen and consulting fees from RottaPharm, and has held nonremunerative positions of influence for Novartis and Roche.
A. Kavanaugh has received research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB. E. Fudman has received research grants from AstraZeneca, Astellas, Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi-Aventis. E.L. Duffield is an employee of AstraZeneca and holds stocks/shares in AstraZeneca. K. Lampl and C. O’Brien are former employees of AstraZeneca and hold stocks/shares in AstraZeneca.
J. Poiley has received research grants from AstraZeneca. M. Weinblatt has received research grants from Crescendo Bioscience, Bristol-Myers Squibb and UCB, has received consulting fees from AbbVie, Ablynx, Adheron Therapeutics, Amgen, Antares, AstraZeneca, Augurex, Bristol-Myers Squibb, Canfite, Crescendo Bioscience, Ensemble, Exagen, Five Prime, Genentech/Roche, Hutchison, Idera, Infinity, Janssen, Lycera, Lilly, Medimmune, Merck, Novo Nordisk, Pfizer, Regeneron, UCB and Vertex, and holds stocks/shares in Canfite, Ensemble and Lycera.
M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O’Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women’s Hospital.
Address correspondence to Dr. M.C. Genovese, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu.
Accepted for publication July 24, 2014.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist
Mark C. Genovese, Désirée M. van der Heijde, Edward Keystone, Alberto J. Spindler, Claude Benhamou, Arthur Kavanaugh, Edward Fudman, Kathy Lampl, Chris O’Brien, Emma L. Duffield, Jeffrey Poiley, Michael E. Weinblatt
The Journal of Rheumatology Sep 2014, jrheum.140238; DOI: 10.3899/jrheum.140238
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist
Mark C. Genovese, Désirée M. van der Heijde, Edward Keystone, Alberto J. Spindler, Claude Benhamou, Arthur Kavanaugh, Edward Fudman, Kathy Lampl, Chris O’Brien, Emma L. Duffield, Jeffrey Poiley, Michael E. Weinblatt
The Journal of Rheumatology Sep 2014, jrheum.140238; DOI: 10.3899/jrheum.140238